ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0544

Prevalence and Baseline Characteristics associated with Difficult-to-Manage Axial Spondyloarthritis in the DESIR Cohort

Olivier Fakih1, Anna Molto2, Frank Verhoeven1, Clément Prati1 and WENDLING Daniel1, 1CHU de Besançon, Besançon, Franche-Comte, France, 2Assistance Publique Hôpitauxde Paris, Paris, France

Meeting: ACR Convergence 2025

Keywords: Cohort Study, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Despite a choice of multiple targeted DMARDs, with different modes of action (MoA), a number of patients with axial spondyloarthritis (axSpA) have failed several treatments. This seems to correspond to a population with specific characteristics that can be termed Difficult to Manage (D2M). A definition of D2M axial spondyloarthritis (D2M-axSpA) has been proposed by the ASAS. Studies using variable definitions estimated a D2M-axSpA prevalence between 10–30%. However, no large cohort study has been conducted based on the ASAS definition. The objective of this study was to determine the prevalence of and factors associated with D2M-axSpA in the DESIR cohort of early inflammatory back pain.

Methods: Patients from the DESIR inception cohort who met the 2009 ASAS criteria for axSpA were included. The baseline characteristics and follow-up data were collected for up to 10 years. Patients were considered to have D2M-axSpA if they failed ≥ 3 bDMARDs and at least one of the sub-criteria making up criterion 2 of the ASAS D2M-axSpA definition (ASDAS ≥ 2.1, signs or symptoms suggestive of active disease, rapid radiographic spinal progression, and reduction in quality of life). This choice reflected limited access to IL-17 inhibitors in this cohort (inclusion in the late 2000s), making it difficult to apply a definition with failure of two different MoA (criterion 1 of the ASAS D2M-axSpA definition). Perception of difficult management (criterion 3) was not assessed. The prevalence of D2M-axSpA was determined, followed by bivariate analysis of the baseline factors associated with the existence of D2M-axSpA. A multivariate analysis using logistic regression was also performed. Quantitative variables were compared using the Mann-Whitney U test and qualitative variables were compared using Fisher’s exact test.

Results: A total of 420 patients were included, mean age of 31.5±7.33 years. A total of 221 (52.6%) patients were women and 368 were HLA-B27 positive (87.62%). The mean follow-up duration was 8.9±2.4 years. The mean ASDAS-crp at inclusion was 2.61±0.98, BASFI was 28.8±22.4, and ASQOL 8.87±5.05. 84 (20%) patients had radiographic sacroiliitis. Fifteen patients (8.4% of bDMARD-treated; 3.6% of all) met the D2M-axSpA definition. D2M-axSpA was associated with female sex and higher ASDAS-CRP, BASFI, and ASQOL at baseline (Table). In a multivariate model adjusted for follow-up duration, only ASQOL at baseline was associated with the occurrence of D2M-axSpA (Odds-ratio 1.28 [1.04-1.63], p=0.03). All included patients met several sub-criteria of the definition, including impairment of the quality of life. None of the patients showed rapid radiographic spinal progression (Figure). A sensitivity analysis showed that seven (1.6%) patients met criteria 1 (failure of ≥ 2 bDMARDs with different MoA) and 2 of the ASAS definition of D2M-axSpA.

Conclusion: The prevalence of D2M-axSpA was low in this cohort of patients with early axSpA, although it was not possible to prescribe a class other than TNF inhibitors during the early years of follow-up. Female sex and high activity, functional, and quality of life scores at baseline were associated with a higher probability of D2M-axSpA, unlike peripheral or extra-musculoskeletal involvement.

Supporting image 1Table: Comparison of characteristics between D2M-axSpA and non-D2M-axSpA patients.

Supporting image 2Venn diagram of sub-criteria 2 of the D2M-axSpA definition.


Disclosures: O. Fakih: None; A. Molto: AbbVie/Abbott, 2, 5, 6, BIOGEN, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 5, 6, Eli Lilly, 2, 5, 6, Galapagos, 2, 5, Janssen, 2, 5, 6, Merck/MSD, 2, 5, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB Pharma France, 1, 6; F. Verhoeven: None; C. Prati: None; W. Daniel: None.

To cite this abstract in AMA style:

Fakih O, Molto A, Verhoeven F, Prati C, Daniel W. Prevalence and Baseline Characteristics associated with Difficult-to-Manage Axial Spondyloarthritis in the DESIR Cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/prevalence-and-baseline-characteristics-associated-with-difficult-to-manage-axial-spondyloarthritis-in-the-desir-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-baseline-characteristics-associated-with-difficult-to-manage-axial-spondyloarthritis-in-the-desir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology